Dataset Information

Label-Free LC-MS/MS Proteomic Analysis of Urinary Identification in Diabetic Vascular Dementia

ABSTRACT: Objective: The aim of this study was to identify novel diagnostic biomarkers of diabetic vascular dementia (DVD) and unraveling the underlying mechanisms using mass spectrometry (MS). Methods: Label-Free LC-MS/MS proteomics analysis was applied to urine samples from four groups including 14 vascular dementia CC(VD), 22 type 2 diabetes mellitus (T2DM), 12 DVD, 21 Normal Control (NC). Searching the MS data by Proteome Discoverer software, protein abundances were analyzed qualitatively and quantitatively and compared between these groups. Combining bioinformatics analysis using GO, pathway crosstalk analysis using KEGG, PPI network analysis using STRING and literature searching, the differentially expressed proteins (DEPs) of DVD can be comprehensively judged and were further quantified by receiver operating characteristic (ROC) curve methods. Results: The proteomic findings showed quantitative changes in DVD was compared to NC, T2DM, and VD groups; among 7,527 identified urine proteins, 1222, 1152, and 1180 of the proteins displayed quantitative changes unique to DVD vs NC, T2DM, and VD, respectively, including 481 overlapped common DEPs. Then 9 unique proteins and 2 composite markers (CM) were confirmed by a ROC curve method. Conclusion: This study provided a novel insight into the potential pathogenesis of DVD and elucidated a method for the earlier detection.

INSTRUMENT(S): Q Exactive HF, Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Urine

SUBMITTER: Yi Zeng

LAB HEAD: Yi Zeng

PROVIDER: PXD022189 | Pride | 2021-01-14

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	017435_HF3_XiangYa_Hospital_T2DM-12per_F1_R1.raw	Raw
	017436_HF3_XiangYa_Hospital_T2DM-12per_F1_R1.raw	Raw
	017437_HF3_XiangYa_Hospital_VDT2DM-12per_F1_R1.raw	Raw
	017439_HF3_XiangYa_Hospital_T2DM-12per_F1_R1.raw	Raw
	017440_HF3_XiangYa_Hospital_T2DM-12per_F1_R1.raw	Raw

Items per page:

1 - 5 of 71

Similar Datasets

Project description:Type 1 diabetes mellitus (T1DM) results from immune mediated destruction of pancreatic beta cells. However, clinical and immunologic phenotypes of T1DM are variable. Several auto-antibodies including GADA, IA-2A, and ZnT8A, were identified in T1DM, but the prevalence of these auto-antibodies varied for a broad spectrum of T1DM. Here, we systemically profiled auto-antibodies from serum samples of 16 T1DM, 16 type 2 diabetes (T2DM) patients, and 27 healthy controls with normal glucose tolerance (NGT) using protein microarrays containing 9,480 proteins. Among 9,480 different proteins on the array, we identified novel auto-antibody candidates (EEF1A1-AAb and UBE2L3-AAb) by M-test coupled with PLS-DA. These auto-antibodies were highly present in T1DM than controls and detected in 40% of T1DM without GADA. Furthermore, these auto-antibodies might help to differentiate subtype of T1DM when combined with GADA. These novel auto-antibodies provide new diagnostic information of T1DM, as well as new insights into the pathogenesis of T1DM. Auto-antibodies from serum samples were profiled using a high-density, fluorescence-based protein microarray containing duplicate spots of 9,480 human proteins derived from the Ultimate ORF collection The cohort of patients and controls consisted of 16 T1DM, 16 T2DM patients, and 27 healthy controls with NGT. This cohort was used to screen candidate auto-antibodies using protein microarrays (ProtoArray platform version 5.0, Invitrogen Corp., Carlsbad, CA). Serum samples were drawn from T1DM patients who have 1) fasting C-peptide level <0.3 nmol/L or serum C-peptide <0.6 nmol/L after glucagon loading, 2) initiation of insulin treatment within six months after diagnosis, and 3) duration of diabetes M-bM-^IM-$12 months. Mean age of T1DM in the first cohort was 42 M-BM-1 16 years. The control serum samples were obtained from T2DM patients who were treated only with oral anti-diabetic drug at least 5 years and from NGTs who had no history of diabetes, no first-degree relatives with diabetes, a fasting plasma glucose concentration of <6.1 mmol/l, and a HbA1c value of <5.8%.

Project description:Protein O-glycosylation has long been recognized to be closely associated with many diseases, particularly with tumor proliferation, invasion and metastasis. The ability to efﬁciently proﬁle the variation of O-glycosylation in large-scale clinical samples provides an important approach for the development of biomarkers for cancer diagnosis and for therapeutic response evaluation. Therefore, mass spectrometry (MS)-based techniques for high throughput, in-depth and reliable elucidation of protein O-glycosylation in large clinical cohorts are in high demand. However, the wide existence of serine and threonine residues in the proteome and the tens of mammalian O-glycan types lead to extremely large searching space composed of millions of theoretical combinations of peptides and O-glycans for intact O-glycopeptide database searching. As a result, exceptionally long time is required for database searching which is a major obstacle in O-glycoproteome studies of large clinical cohorts. More importantly, due to the low abundance and poor ionization of intact O-glycopeptides and the stochastic nature of data-dependent MS2 acquisition, substantially elevated missing data levels are inevitable as the sample number increases, which undermines the quantitative comparison across samples. Therefore, we report a new MS data processing strategy that integrates glycoform-specific database searching, reference library-based MS1 feature matching and MS2 identification propagation for fast identification, in-depth and reproducible label-free quantification of O-glycosylation of human urinary proteins. This strategy increases the database searching speeds by up to 20-fold and leads to a 30-40% enhanced intact O-glycopeptide quantification in individual samples with an obviously improved reproducibility. In total, we obtained quantitative information for 1068 intact O-glycopeptides across 36 healthy human urine samples with a 30-40% reduction in the amount of missing data. This is currently the largest dataset of urinary O-glycoproteome and demonstrates the application potential of this new strategy in large-scale clinical investigations.

Dataset Information

Label-Free LC-MS/MS Proteomic Analysis of Urinary Identification in Diabetic Vascular Dementia

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets